Veronal is the brand name for barbital, the first barbiturate ever marketed as a medicine. Introduced in 1903 as a sleeping pill, it was wildly popular for decades before doctors and regulators realized it had a dangerous flaw: the dose needed to put someone to sleep was not far from the dose that could kill them. That narrow margin, combined with its tendency to cause physical dependence, ultimately drove Veronal off the market as safer sedatives arrived in the mid-twentieth century.
How Veronal Came to Exist
The story starts in 1864, when the German chemist Adolf von Baeyer synthesized malonylurea, the core chemical backbone of all barbiturates. That compound sat in the chemistry literature for nearly four decades without anyone recognizing its medical potential. It was not until 1903 that two other German scientists, Emil Fischer and Joseph von Mering, discovered that a derivative of malonylurea called diethylbarbituric acid could reliably put laboratory animals to sleep. They named the compound “Veronal,” reportedly because von Mering considered Verona the most peaceful city he had ever visited, though the origin of the name is debated. Fischer and von Mering published their results, and the drug was brought to market the same year by the Bayer pharmaceutical company.1PubMed Central. The history of barbiturates a century after their clinical introduction
The timing mattered. In the early 1900s, the main options for inducing sleep were alcohol, opium-derived preparations, chloral hydrate, and bromides. All of these had obvious problems ranging from unreliable dosing to severe side effects. Veronal, by contrast, could be taken as a tablet, worked predictably, and produced a sleep that felt relatively natural. Doctors embraced it almost immediately, and it became one of the most prescribed drugs of the early twentieth century.
What Veronal Does in the Brain
Veronal works by amplifying the brain’s own braking system. The brain uses a chemical messenger called GABA to slow down nerve-cell activity, and barbiturates like Veronal make GABA’s calming effect stronger and longer-lasting. At the receptor level, the drug extends the time that chloride channels stay open when GABA binds to them, which makes neurons harder to fire. At higher concentrations, barbiturates can activate those same receptors directly, without GABA being present at all.2PubMed. How theories evolved concerning the mechanism of action of barbiturates
That second property is the crux of the danger. Most modern sedatives only enhance the GABA signal that is already there; they cannot push the system past a certain ceiling. Barbiturates can. Because they can directly force those receptors open, a large enough dose suppresses brain activity to the point where basic functions like breathing shut down. This is why barbiturate overdoses are so lethal compared to overdoses of the drugs that eventually replaced them.
What Doctors Used It For
Veronal’s primary role was as a hypnotic, a drug given specifically to produce sleep. Patients with insomnia were the bread and butter of barbital prescriptions for the first two decades of the twentieth century. But doctors quickly found other uses. The calming effect at lower doses made it useful as a daytime sedative for anxiety, and it was sometimes used to manage agitation in psychiatric patients.
Barbiturates as a class expanded well beyond what Veronal itself was used for. The discovery that phenobarbital could control epileptic seizures opened an entirely new therapeutic category. Thiobarbiturates like thiopental became the standard for inducing anesthesia before surgery. Some psychiatrists even experimented with prolonged barbiturate-induced sleep as a treatment for schizophrenia, a practice known as “sleep cures” that was later abandoned.1PubMed Central. The history of barbiturates a century after their clinical introduction
Veronal itself, though, remained a sleeping pill. It was a long-acting barbiturate, meaning its effects lingered in the body for many hours. That made it effective for getting a full night of sleep but less useful for other purposes where a shorter duration was preferable. As newer barbiturates with different speed profiles became available, Veronal gradually lost market share even within the barbiturate family, well before barbiturates themselves fell out of favor.
The Safety Problem That Ended Barbiturate Dominance
Barbiturates have a narrow therapeutic index, which is a way of saying the gap between a dose that works and a dose that kills is uncomfortably small. For Veronal, a therapeutic dose might be a few hundred milligrams, and a lethal dose might be only a few times that amount. Compare this to something like ibuprofen, where the lethal dose is many dozens of times the therapeutic dose, and you can see the problem. Even a modest miscalculation, or a patient taking a second dose because the first had not yet kicked in, could be fatal.
Reports of Veronal poisoning appeared in medical literature within years of the drug’s introduction. By the 1920s, physicians were already publishing case reports of acute barbital poisoning in major medical journals, documenting the progression from deep unconsciousness to respiratory failure.3Journal of the American Medical Association. ACUTE VERONAL (BARBITAL) POISONING: REPORT OF A CASE Intentional overdoses were also a growing concern; barbiturates became a common method of suicide throughout the first half of the twentieth century, and Veronal featured prominently in that grim statistic.
Treatment options for barbiturate overdose in the early decades were crude. There were no specific antidotes. Physicians relied on supportive measures: stimulants to try to keep the patient awake, intravenous fluids, and later, forced diuresis to accelerate the drug’s elimination through the kidneys. Barbital’s long half-life meant that patients who survived an overdose could remain comatose for days.
Dependence and Withdrawal
Beyond the overdose risk, prolonged use of Veronal and other barbiturates produced physical dependence. The brain adapted to the constant suppression of neural activity by becoming more excitable to compensate. When the drug was withdrawn, that heightened excitability had nothing counteracting it, leading to withdrawal symptoms that could include anxiety, tremors, seizures, and in severe cases, delirium and death.
Barbiturate withdrawal is, by medical consensus, among the most dangerous of any drug class, comparable to alcohol withdrawal and more hazardous than opioid withdrawal. Patients who had been taking Veronal nightly for months or years could not simply stop. They required carefully supervised tapering, and even then the process was risky. These dependence and safety concerns, viewed alongside the rising death toll from overdoses, created the conditions for barbiturates to be displaced once anything better came along.1PubMed Central. The history of barbiturates a century after their clinical introduction
What Replaced Veronal
The “something better” arrived in the 1960s in the form of benzodiazepines. Chlordiazepoxide (Librium) was introduced in 1960, followed by diazepam (Valium) in 1963. These drugs worked on the same GABA system but with an important difference: benzodiazepines enhance GABA’s action without being able to directly activate the receptor on their own. This gives them a built-in ceiling effect. You can take a very large dose of a benzodiazepine and, while you will become profoundly sedated, your brainstem is far less likely to shut down the way it does with barbiturates. The improved therapeutic index meant fewer accidental deaths and fewer successful suicide attempts.4PubMed Central. Benzodiazepines at the crossroads: navigating therapeutic promise and perils of misuse
The transition was rapid. By the 1970s, benzodiazepines had largely replaced barbiturates for insomnia and anxiety. Barbiturate prescriptions plummeted. Veronal, already an aging product within its own drug class, disappeared from clinical use. Phenobarbital held on longer because of its established role in epilepsy treatment, and thiopental remained in anesthesia for decades, but the broad category of barbiturates as everyday sedatives was effectively finished.
Benzodiazepines turned out to have their own dependence issues and are now themselves increasingly scrutinized. But the key distinction remains: a benzodiazepine overdose taken alone is rarely fatal, while a barbiturate overdose frequently is. That single difference was enough to end the barbiturate era.
Where Barbiturates Still Have a Role
Barbiturates did not vanish entirely. Phenobarbital is still used for certain types of epilepsy, particularly in resource-limited settings where it remains one of the cheapest and most available anticonvulsants. Thiopental and methohexital are still used occasionally in anesthesia, though propofol has largely taken over that role as well. In veterinary medicine, pentobarbital is the standard agent for euthanasia. And in the United States, barbiturates have figured controversially in lethal injection protocols, though sourcing difficulties and legal challenges have complicated that use.
Veronal specifically has no remaining clinical role anywhere. Its long duration of action, which was seen as an advantage in the early 1900s, became a liability once shorter-acting barbiturates were available for the few remaining indications. There is no niche left for it to fill.
Veronal’s Quiet Afterlife in the Laboratory
One place where the name “Veronal” persists, in a form that would surprise most people, is the biochemistry lab. Barbital turns out to be an excellent pH buffer for certain kinds of electrophoresis, a technique used to separate proteins and other molecules. “Veronal buffer” or “barbital buffer” at a specific pH has been a standard reagent in laboratory protocols for decades.5ScienceDirect. Agarose electrophoresis of subtilisin Carlsberg in veronal buffer at pH 6.5 In this context, barbital is valued not for anything it does to the nervous system but for its chemical stability and reliable buffering capacity in a useful pH range. Regulatory restrictions on barbiturates have made sourcing it more cumbersome for labs, and some have switched to alternative buffers, but Veronal buffer remains in use in certain diagnostic and research settings.
The Drug’s Place in Cultural History
Veronal occupies an outsized place in literary and cultural history relative to its pharmacological importance. It shows up repeatedly in early twentieth-century fiction as the sleeping drug of choice, a detail that reflects how ubiquitous it was in daily life. Agatha Christie, who trained as a pharmacist’s assistant and had real knowledge of drugs, featured barbital poisoning in her mystery plots. Virginia Woolf reportedly used Veronal as a sleep aid. The drug appeared in works by Thomas Mann and other European writers of the interwar period, often as shorthand for the era’s complicated relationship with modern medicine: miraculous and dangerous in equal measure.
The cultural familiarity with Veronal also reflected something darker. Before barbiturates, suicide by poisoning typically involved substances that caused painful, protracted deaths. Veronal offered something that seemed like a peaceful alternative, and the rate of suicidal overdoses climbed steeply after its introduction. This contributed to public pressure for tighter pharmaceutical regulation throughout the early twentieth century, and the barbiturate overdose crisis is one of the historical threads that led to the modern system of prescription drug controls in many countries.
How Veronal Compares to Its Barbiturate Successors
More than 2,500 barbiturate compounds have been synthesized since von Baeyer’s original 1864 work, though only about 50 were ever used clinically. These drugs differ mainly in how quickly they take effect and how long they last. Veronal (barbital) sits at the long-acting end of the spectrum, with effects that could persist for well over twelve hours. Phenobarbital, introduced in 1912, is also long-acting but proved more useful because of its anticonvulsant properties. Shorter-acting barbiturates like pentobarbital and secobarbital became the preferred sleeping pills by mid-century because they wore off faster and left patients less groggy the next day.
The differences in potency and duration among barbiturates are related to how readily each compound crosses into the brain and how it interacts with nerve-cell membranes. Research comparing barbital, phenobarbital, and pentobarbital found that their ability to integrate into cell membranes and block nerve signaling increases in that order, which tracks with their clinical potency.6PubMed Central. Surface activities of barbital, phenobarbital, and pentobarbital and their interaction energies with phospholipid monolayers Barbital, in other words, was the least potent of the commonly used barbiturates, which is partly why it required relatively large doses to work and partly why it stuck around in the body for so long.
Why You Still Hear About Barbiturates
Despite being largely retired from mainstream medicine, barbiturates remain relevant in a few ongoing conversations. One is the “right to die” movement: organizations advocating for medically assisted death have historically favored pentobarbital as the agent of choice, and access to it has become a flashpoint in legal and ethical debates. Another is forensic toxicology, where barbiturates still show up in postmortem analyses and are part of standard drug-screening panels. And in pharmacology education, barbiturates serve as the textbook example of a drug class displaced by safer alternatives, a cautionary tale about therapeutic index that every pharmacy student learns early on.
Recreational misuse of barbiturates, once a major public health concern, has declined dramatically but has not disappeared. Street availability is low compared to the mid-twentieth century, but diverted pharmaceutical supplies still circulate. Emergency physicians occasionally see barbiturate overdoses, and the treatment approach has not changed much: maintain the airway, support breathing, and wait for the drug to clear. There is still no specific reversal agent for barbiturate poisoning, unlike the situation with benzodiazepines (which can be reversed with flumazenil) or opioids (which can be reversed with naloxone). That lack of an antidote is yet another reminder of why these drugs fell out of routine use.